Precision Diagnostics & Medicine Market - Global Forecast to 2029
商品番号 : SMB-42657
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年1月 |
| ページ数 | 446 |
| 図表数 | 508 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global Precision Diagnostics and Medicine market is projected to reach USD 246.66 billion in 2029 from USD 145.53 billion by 2024, at a CAGR of 11.1% during the forecast period. Factors such as the ongoing integration of advanced technologies such as artificial intelligence and machine learning to enhance precision medicine development, supported by the rising collaboration and investments by major pharmaceutical and diagnostics companies to develop better precision medicine solutions are supporting the growth of the market.
世界の精密診断と医療市場は、2024年までに1,455億3,000万米ドルから2029年には2,466億6,000万米ドルに達し、予測期間中に11.1%のCAGRで成長すると予測されています。より優れた精密医療ソリューションを開発するための大手製薬会社や診断会社による協力や投資の増加に支えられ、精密医療開発を強化するための人工知能や機械学習などの先進技術の継続的な統合などが市場の成長を支えています。
Moreover, the expanding focus of these companies to develop precision therapies and diagnostic tests for multiple diseases such as neurodegenerative and autoimmune diseases highlight the growing importance of precision medicine in healthcare. Additionally, the increasing awareness of patients regarding their health is supporting the adoption of wearable medical devices and direct-to-consumer precision diagnostic tests offering growth opportunities to players in this market. However, the high cost of precision healthcare and challenges associated with the integration and management of big data in healthcare are expected to restrain the growth of this market.
“The monoclonal antibodies segment registered the highest growth rate in the precision medicine market, by products, during the forecast period”
In 2023, the monoclonal antibodies segment registered the highest growth rate within the precision medicine market by products. Factors such as the increasing collaborations to develop advanced monoclonal antibodies and advancements in antibody engineering technologies are attributed to the growth of this segment. Additionally, these modalities offer various advantages over traditional drugs such as high specificity, low toxicity, and longer-lasting effects among others increasing the adoption of these drug modalities for the treatment of cancer, autoimmune, and infectious diseases supporting the growth of this segment.
“The hospitals and clinics end user segment registered the highest growth rate and largest market share in the precision medicine market, by end user, during the forecast period”
The hospitals and clinic end users registered the highest growth rate within the precision medicine market by end user segment during the forecast period. Factors such as the growing demand for personalized treatments and the ability of hospitals and clinics to offer personalized therapies in a controlled environment can be attributed to the large share of this end user segment. Moreover, the rising collaborations between hospitals and pharmaceutical and diagnostic companies to develop personalized therapies and diagnostic tests support the growth of this segment. Hospitals and clinics act as data reservoirs for these companies which gather real-world data from these institutions for the development of advanced precision solutions. This high growth is projected to continue during the forecast period.
“Asia Pacific: The fastest growing region in the Precision Diagnostics market”
The precision diagnostics market of Asia Pacific is projected to register the highest growth rate during the forecast period. This high growth is attributed to the rising cases of chronic diseases, cancer, and genetic disorders in this region leading to a growing demand for precision diagnostics solutions. This growth is supported by investments in healthcare infrastructure across countries like China, India, and Japan, enhancing access to advanced diagnostic technologies. Additionally, the adoption of technologies like next-generation sequencing (NGS), artificial intelligence, and machine learning is driving innovations in the field. Government initiatives and improved healthcare coverage also contribute to expanding access to precision diagnostics. Moreover, the support and funding from government organizations for life sciences research and development also support the rapid growth of the Asia Pacific precision diagnostics market.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 44%, Tier 2 – 32%, and Tier 3 – 24%
- By Designation: (Managers) – 45%, (CXOs, Directors)- 30%, and(Executives) – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15%
List of Companies Profiled in the Report:
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Agilent Technologies, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Myriad Genetics, Inc. (US)
- Guardant Health (US)
- Abbott (US)
- Natera Inc. (US)
- Illumina, Inc. (US)
- Danaher (US)
- Exact Sciences Corporation (US)
- Qiagen (Netherlands)
- 23andME, INC. (US)
- ARUP Laboratories. (US)
- Devyser (Sweden)
- Diasorin S.P.A. (Italy)
- Tempus (US)
- Pillar Biosciences Inc. (US)
- Invivoscribe, Inc. (US)
- NeuroCode (US)
- C₂N Diagnostics (US)
- Trinity Biotech Plc. (Ireland)
- Amoy Diagnostics Co., Ltd. (China)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb Company (US)
- Gilead Sciences, Inc. (US)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Eli Lilly and Company. (US)
- Pfizer Inc. (US), GSK plc. (UK)
- Sanofi (France)
- Johnson & Johnson Services, Inc. (US)
- Vertex Pharmaceuticals Incorporated (US)
- Amgen Inc. (US)
- Merck KGaA (Germany)
- Sarepta Therapeutics, Inc. (US).
Research Coverage:
This report provides a detailed picture of the global Precision Diagnostics and Medicine Market. It aims to estimate the size and future growth potential of the market across different segments such as the precision diagnostics market (type, indication, and end user) and precision medicine market (product, indication, and end user) region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the precision diagnostics and medicine market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the precision diagnostics and medicine market. Competitive analysis of upcoming startups in the precision diagnostics and medicine market ecosystem is covered in this report.
Reasons to buy this report :
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall precision diagnostics and medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing Integration Of AI And ML To Improve Precision Diagnostics And Therapy Development, Rising Collaborations Between Pharmaceutical And Diagnostics Company To Enhance Precision Healthcare and Rise in direct-to-consumer testing), restraints (High costs of precision healthcare and Slow Pace Of Reimbursement For Precision Diagnostics), opportunities (Expanding The Application Of Precision Diagnostics From Oncology and Integration of wearable devices to enhance precision healthcare), and challenges (Challenges in Regulatory Approval for Diagnostics and Big Data Management and Integration) influencing the growth of the precision diagnostics and medicine market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches and approvals in the precision diagnostics and medicine market
- Market Development: Comprehensive information about lucrative markets – the report analyses the precision diagnostics and medicine market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the precision diagnostics and medicine market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players in precision diagnostics market like- F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Agilent Technologies, Inc. (US), Guardant Health (US), Thermo Fisher Scientific Inc. (US), Myriad Genetics, Inc. (US) among others and precision medicine market like- Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US) Gilead Sciences, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Novartis AG (Switzerland), among others.
Table of Contents
1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 35
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 35
1.3.2 INCLUSIONS AND EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 37
1.4 CURRENCY CONSIDERED 37
1.5 STAKEHOLDERS 37
1.6 SUMMARY OF CHANGES 38
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.1.1 SECONDARY DATA 40
2.1.2 PRIMARY DATA 40
2.2 MARKET SIZE ESTIMATION METHODOLOGY 41
2.2.1 PRECISION DIAGNOSTICS MARKET 41
2.2.2 PRECISION MEDICINE MARKET 44
2.2.3 INSIGHTS FROM PRIMARY SOURCES 46
2.3 TOP-DOWN APPROACH 47
2.3.1 PRECISION DIAGNOSTICS MARKET 47
2.3.2 PRECISION MEDICINE MARKET 48
2.4 GROWTH FORECAST MODEL 49
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 51
2.6 RESEARCH ASSUMPTIONS 52
2.7 RESEARCH LIMITATIONS 52
2.8 RISK ANALYSIS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 58
4.1 PRECISION DIAGNOSTICS MARKET OVERVIEW 58
4.2 PRECISION MEDICINE MARKET OVERVIEW 59
4.3 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND COUNTRY, 2023 60
4.4 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 60
4.5 PRECISION DIAGNOSTICS MARKET, BY END USER, 2023 61
4.6 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023 61
4.7 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029 62
4.8 PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62
4.9 PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Increasing collaborations between pharmaceutical and diagnostic companies 65
5.2.1.2 Rise in direct-to-consumer testing 66
5.2.1.3 Growing integration of artificial intelligence and machine learning 66
5.2.2 RESTRAINTS 67
5.2.2.1 High cost of precision healthcare 67
5.2.3 OPPORTUNITIES 67
5.2.3.1 Expanding applications of precision healthcare 67
5.2.3.2 Growing adoption of wearable devices 68
5.2.4 CHALLENGES 68
5.2.4.1 Complex regulatory approval landscape 68
5.2.4.2 Big data management and integration issues 69
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 69
5.4 PRICING ANALYSIS 70
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 70
5.4.2 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER 72
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION 73
5.5 VALUE CHAIN ANALYSIS 74
5.5.1 PRECISION DIAGNOSTICS MARKET 74
5.5.2 PRECISION MEDICINE MARKET 76
5.6 SUPPLY CHAIN ANALYSIS 77
5.6.1 PRECISION DIAGNOSTICS MARKET 77
5.6.2 PRECISION MEDICINE MARKET 78
5.7 ECOSYSTEM ANALYSIS 79
5.8 PIPELINE ANALYSIS 81
5.9 DIAGNOSTIC PRODUCT ANALYSIS 83
5.10 INVESTMENT/FUNDING ACTIVITY 96
5.11 TECHNOLOGY ANALYSIS 97
5.11.1 KEY TECHNOLOGIES 97
5.11.1.1 Next-generation sequencing 97
5.11.1.2 Immunohistochemistry 97
5.11.1.3 Liquid biopsy 97
5.11.2 COMPLEMENTARY TECHNOLOGIES 98
5.11.2.1 Single-cell analysis 98
5.11.2.2 AI and ML integration 98
5.11.3 ADJACENT TECHNOLOGIES 98
5.11.3.1 Theranostics 98
5.11.3.2 Imaging technologies 99
5.12 PATENT ANALYSIS 99
5.13 TRADE ANALYSIS 102
5.13.1 IMPORT DATA 102
5.13.2 EXPORT DATA 104
5.14 KEY CONFERENCES AND EVENTS, 2025–2026 106
5.15 REGULATORY LANDSCAPE 107
5.15.1 REGULATORY ANALYSIS 107
5.15.1.1 North America 107
5.15.1.2 Europe 108
5.15.1.3 Asia Pacific 108
5.15.1.4 Rest of the World 108
5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
5.16 PORTER’S FIVE FORCES ANALYSIS 112
5.16.1 PRECISION DIAGNOSTICS MARKET 112
5.16.1.1 Threat of new entrants 113
5.16.1.2 Threat of substitutes 113
5.16.1.3 Bargaining power of buyers 114
5.16.1.4 Bargaining power of suppliers 114
5.16.1.5 Intensity of competitive rivalry 114
5.16.2 PRECISION MEDICINE MARKET 114
5.16.2.1 Threat of new entrants 115
5.16.2.2 Threat of substitutes 115
5.16.2.3 Bargaining power of buyers 115
5.16.2.4 Bargaining power of suppliers 116
5.16.2.5 Intensity of competitive rivalry 116
5.17 KEY STAKEHOLDERS AND BUYING CRITERIA 116
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS 116
5.17.2 BUYING CRITERIA 119
5.18 IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET 121
5.18.1 INTRODUCTION 121
5.18.2 MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES 121
5.18.3 AI USE CASES 122
5.18.4 KEY COMPANIES IMPLEMENTING AI 123
5.18.5 FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND
MEDICINE ECOSYSTEM 123
6 PRECISION DIAGNOSTICS MARKET, BY TYPE 124
6.1 INTRODUCTION 125
6.2 GENETIC TESTING 125
6.2.1 NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH 125
6.3 DTC TESTING 127
6.3.1 INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO
ENCOURAGE GROWTH 127
6.4 OTHER TYPES 130
7 PRECISION DIAGNOSTICS MARKET, BY INDICATION 132
7.1 INTRODUCTION 133
7.2 ONCOLOGY 133
7.2.1 RISING CANCER CASES TO ACCELERATE GROWTH 133
7.3 NEUROLOGY 136
7.3.1 INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET 136
7.4 IMMUNOLOGY 138
7.4.1 GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET 138
7.5 OTHER DIAGNOSTIC INDICATIONS 140
8 PRECISION DIAGNOSTICS MARKET, BY END USER 143
8.1 INTRODUCTION 144
8.2 CLINICAL LABORATORIES 144
8.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH 144
8.3 HOSPITALS 146
8.3.1 GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET 146
8.4 HOME CARE SETTINGS 148
8.4.1 INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH 148
9 PRECISION MEDICINE MARKET, BY PRODUCT 151
9.1 INTRODUCTION 152
9.2 MONOCLONAL ANTIBODIES 152
9.2.1 RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH 152
9.3 INHIBITOR DRUGS 154
9.3.1 INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH 154
9.4 CELL & GENE THERAPIES 157
9.4.1 GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET 157
9.5 ANTIVIRAL & ANTI-RETROVIRAL DRUGS 159
9.5.1 NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH 159
9.6 OTHER PRODUCTS 161
10 PRECISION MEDICINE MARKET, BY INDICATION 164
10.1 INTRODUCTION 165
10.2 ONCOLOGY 165
10.2.1 GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET 165
10.3 RARE DISEASES 167
10.3.1 SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH 167
10.4 INFECTIOUS DISEASES 170
10.4.1 NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET 170
10.5 HEMATOLOGICAL DISORDERS 172
10.5.1 INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES TO AUGMENT GROWTH 172
10.6 OTHER MEDICINE INDICATIONS 174
11 PRECISION MEDICINE MARKET, BY END USER 177
11.1 INTRODUCTION 178
11.2 HOSPITALS & CLINICS 178
11.2.1 GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET 178
11.3 HOME CARE SETTINGS 180
11.3.1 INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES TO EXPEDITE GROWTH 180
12 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION 183
12.1 INTRODUCTION 184
12.2 NORTH AMERICA 184
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 188
12.2.2 US 189
12.2.2.1 Well-established infrastructure and availability of advanced treatments to augment growth 189
12.2.3 CANADA 191
12.2.3.1 Growing cancer burden to support growth 191
12.3 EUROPE 194
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 198
12.3.2 GERMANY 199
12.3.2.1 Growing collaborations between research institutions and healthcare providers to boost market 199
12.3.3 UK 201
12.3.3.1 Favorable government support to expedite growth 201
12.3.4 FRANCE 204
12.3.4.1 Growing preference for personalized medicine to fuel market 204
12.3.5 ITALY 206
12.3.5.1 Rise in genomics research and diagnostic testing to foster growth. 206
12.3.6 SPAIN 208
12.3.6.1 Robust network of healthcare systems, research centers, and universities to facilitate growth 208
12.3.7 REST OF EUROPE 211
12.4 ASIA PACIFIC 213
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 216
12.4.2 CHINA 217
12.4.2.1 Growing regulatory approvals for precision medicines to boost market 217
12.4.3 JAPAN 219
12.4.3.1 Increasing availability of health insurance to encourage growth 219
12.4.4 INDIA 222
12.4.4.1 Rising burden of chronic diseases to promote growth 222
12.4.5 AUSTRALIA 224
12.4.5.1 Booming research & development investments to spur growth 224
12.4.6 REST OF ASIA PACIFIC 226
12.5 LATIN AMERICA 228
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 231
12.5.2 BRAZIL 232
12.5.2.1 Growing incorporation of genomic medicine into public healthcare to drive market 232
12.5.3 MEXICO 235
12.5.3.1 Booming biopharmaceutical sector to contribute to growth 235
12.5.4 REST OF LATIN AMERICA 237
12.6 MIDDLE EAST & AFRICA 239
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 242
13 COMPETITIVE LANDSCAPE 244
13.1 OVERVIEW 244
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024 244
13.2.1 PRECISION DIAGNOSTICS MARKET 244
13.2.2 PRECISION MEDICINE MARKET 247
13.3 REVENUE ANALYSIS, 2021–2023 252
13.3.1 PRECISION DIAGNOSTICS MARKET 252
13.3.2 PRECISION MEDICINE MARKET 253
13.4 MARKET SHARE ANALYSIS, 2023 254
13.4.1 PRECISION DIAGNOSTICS MARKET 254
13.4.2 PRECISION MEDICINE MARKET 257
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 260
13.5.1 PRECISION DIAGNOSTICS MARKET 260
13.5.1.1 Stars 260
13.5.1.2 Emerging leaders 260
13.5.1.3 Pervasive players 260
13.5.1.4 Participants 261
13.5.1.5 Company footprint: Key players, 2023 262
13.5.1.5.1 Company footprint 262
13.5.1.5.2 Region footprint 263
13.5.1.5.3 Type footprint 264
13.5.1.5.4 Indication footprint 265
13.5.2 PRECISION MEDICINE MARKET 266
13.5.2.1 Stars 267
13.5.2.2 Emerging leaders 267
13.5.2.3 Pervasive players 267
13.5.2.4 Participants 267
13.5.2.5 Company footprint: Key players, 2023 269
13.5.2.5.1 Company footprint 269
13.5.2.5.2 Region footprint 270
13.5.2.5.3 Product footprint 271
13.5.2.5.4 Indication footprint 272
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 274
13.6.1 PRECISION DIAGNOSTICS MARKET 274
13.6.1.1 Progressive companies 274
13.6.1.2 Responsive companies 274
13.6.1.3 Dynamic companies 274
13.6.1.4 Starting blocks 274
13.6.1.5 Competitive benchmarking 276
13.6.1.5.1 Detailed list of key startups/SMES 276
13.6.1.5.2 Competitive benchmarking of startups/SMEs 277
13.6.2 PRECISION MEDICINE MARKET 278
13.6.2.1 Progressive companies 278
13.6.2.2 Responsive companies 278
13.6.2.3 Dynamic companies 278
13.6.2.4 Starting blocks 278
13.6.2.5 Competitive benchmarking 280
13.6.2.5.1 Detailed list of key startups/SMES 280
13.6.2.5.2 Competitive benchmarking of startups/SMEs 281
13.7 COMPANY VALUATION AND FINANCIAL METRICS 282
13.7.1 PRECISION DIAGNOSTICS MARKET 282
13.7.2 PRECISION MEDICINE MARKET 283
13.8 BRAND/PRODUCT COMPARISON 284
13.9 PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO 285
13.9.1 PRODUCT LAUNCHES AND APPROVALS 286
13.9.2 DEALS 287
13.9.3 EXPANSIONS 288
13.10 PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO 288
13.10.1 PRODUCT LAUNCHES AND APPROVALS 289
13.10.2 DEALS 290
13.10.3 EXPANSIONS 291
14 COMPANY PROFILES 292
14.1 KEY PLAYERS 292
14.1.1 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS) 292
14.1.1.1 Business overview 292
14.1.1.2 Products offered 293
14.1.1.3 Recent developments 297
14.1.1.3.1 Product launches and approvals 297
14.1.1.3.2 Deals 298
14.1.1.4 MnM view 299
14.1.1.4.1 Key strengths 299
14.1.1.4.2 Strategic choices 299
14.1.1.4.3 Weaknesses and competitive threats 299
14.1.2 ABBOTT 300
14.1.2.1 Business overview 300
14.1.2.2 Products offered 301
14.1.2.3 Recent developments 302
14.1.2.3.1 Deals 302
14.1.2.4 MnM view 303
14.1.2.4.1 Key strengths 303
14.1.2.4.2 Strategic choices 303
14.1.2.4.3 Weaknesses and competitive threats 303
14.1.3 AGILENT TECHNOLOGIES, INC. 304
14.1.3.1 Business overview 304
14.1.3.2 Products offered 305
14.1.3.3 Recent developments 307
14.1.3.3.1 Product launches and approvals 307
14.1.3.3.2 Deals 308
14.1.3.3.3 Expansions 308
14.1.3.4 MnM view 308
14.1.3.4.1 Key strengths 308
14.1.3.4.2 Strategic choices 309
14.1.3.4.3 Weaknesses and competitive threats 309
14.1.4 GUARDANT HEALTH 310
14.1.4.1 Business overview 310
14.1.4.2 Products offered 311
14.1.4.3 Recent developments 312
14.1.4.3.1 Product launches and approvals 312
14.1.4.3.2 Deals 314
14.1.4.4 MnM view 315
14.1.4.4.1 Key strengths 315
14.1.4.4.2 Strategic choices 315
14.1.4.4.3 Weaknesses and competitive threats 315
14.1.5 EXACT SCIENCES CORPORATION 316
14.1.5.1 Business overview 316
14.1.5.2 Products offered 317
14.1.5.3 Recent developments 318
14.1.5.3.1 Product launches and approvals 318
14.1.5.3.2 Deals 319
14.1.5.4 MnM view 319
14.1.5.4.1 Key strengths 319
14.1.5.4.2 Strategic choices 319
14.1.5.4.3 Weaknesses and competitive threats 319
14.1.6 QIAGEN 320
14.1.6.1 Business overview 320
14.1.6.2 Products offered 321
14.1.6.3 Recent developments 324
14.1.6.3.1 Product launches and approvals 324
14.1.6.3.2 Deals 325
14.1.7 MYRIAD GENETICS, INC. 326
14.1.7.1 Business overview 326
14.1.7.2 Products offered 327
14.1.7.3 Recent developments 329
14.1.7.3.1 Product launches and approvals 329
14.1.7.3.2 Deals 329
14.1.7.3.3 Other developments 330
14.1.8 NATERA, INC. 331
14.1.8.1 Business overview 331
14.1.8.2 Products offered 332
14.1.8.3 Recent developments 334
14.1.8.3.1 Product launches and approvals 334
14.1.8.3.2 Deals 334
14.1.9 ILLUMINA, INC. 335
14.1.9.1 Business overview 335
14.1.9.2 Products offered 336
14.1.9.3 Recent developments 337
14.1.9.3.1 Product launches and approvals 337
14.1.9.3.2 Deals 337
14.1.10 THERMO FISHER SCIENTIFIC INC. 339
14.1.10.1 Business overview 339
14.1.10.2 Products offered 340
14.1.10.3 Recent developments 341
14.1.10.3.1 Product launches and approvals 341
14.1.10.3.2 Deals 342
14.1.11 DANAHER 344
14.1.11.1 Business overview 344
14.1.11.2 Products offered 345
14.1.11.3 Recent developments 348
14.1.11.3.1 Product launches and approvals 348
14.1.11.3.2 Deals 349
14.1.12 23ANDME, INC. 350
14.1.12.1 Business overview 350
14.1.12.2 Products offered 351
14.1.12.3 Recent developments 353
14.1.12.3.1 Deals 353
14.1.13 MERCK & CO., INC. 354
14.1.13.1 Business overview 354
14.1.13.2 Products offered 355
14.1.13.3 Recent developments 356
14.1.13.3.1 Product launches and approvals 356
14.1.13.3.2 Deals 360
14.1.14 GILEAD SCIENCES, INC. 361
14.1.14.1 Business overview 361
14.1.14.2 Products offered 362
14.1.14.3 Recent developments 364
14.1.14.3.1 Product launches and approvals 364
14.1.14.3.2 Deals 365
14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE) 367
14.1.15.1 Business overview 367
14.1.15.2 Products offered 368
14.1.15.3 Recent developments 371
14.1.15.3.1 Product launches and approvals 371
14.1.16 BRISTOL-MYERS SQUIBB COMPANY 373
14.1.16.1 Business overview 373
14.1.16.2 Products offered 374
14.1.16.3 Recent developments 376
14.1.16.3.1 Product launches and approvals 376
14.1.16.3.2 Deals 378
14.1.17 NOVARTIS AG 379
14.1.17.1 Business overview 379
14.1.17.2 Products offered 380
14.1.17.3 Recent developments 383
14.1.17.3.1 Product launches and approvals 383
14.1.17.3.2 Deals 384
14.1.18 ASTRAZENECA 386
14.1.18.1 Business overview 386
14.1.18.2 Products offered 387
14.1.18.3 Recent developments 389
14.1.18.3.1 Product launches and approvals 389
14.1.18.3.2 Deals 390
14.1.19 ABBVIE INC. 391
14.1.19.1 Business overview 391
14.1.19.2 Products offered 392
14.1.19.3 Recent developments 393
14.1.19.3.1 Product launches and approvals 393
14.1.19.3.2 Deals 393
14.1.19.3.3 Expansions 394
14.1.20 LILLY 395
14.1.20.1 Business overview 395
14.1.20.2 Products offered 396
14.1.20.3 Recent developments 397
14.1.20.3.1 Product launches and approvals 397
14.1.20.3.2 Deals 398
14.1.21 PFIZER INC. 399
14.1.21.1 Business overview 399
14.1.21.2 Products offered 400
14.1.21.3 Recent developments 402
14.1.21.3.1 Product launches and approvals 402
14.1.21.3.2 Deals 402
14.1.22 SAREPTA THERAPEUTICS, INC. 403
14.1.22.1 Business overview 403
14.1.22.2 Products offered 404
14.1.22.3 Recent developments 405
14.1.22.3.1 Product launches and approvals 405
14.1.22.3.2 Deals 406
14.1.23 VERTEX PHARMACEUTICALS INCORPORATED 407
14.1.23.1 Business overview 407
14.1.23.2 Products offered 408
14.1.23.3 Recent developments 409
14.1.23.3.1 Product launches and approvals 409
14.1.23.3.2 Deals 410
14.1.24 GSK PLC. 411
14.1.24.1 Business overview 411
14.1.24.2 Products offered 412
14.1.24.3 Recent developments 413
14.1.24.3.1 Product launches and approvals 413
14.1.24.3.2 Deals 414
14.2 OTHER PLAYERS 416
14.2.1 SANOFI 416
14.2.2 JOHNSON & JOHNSON SERVICES, INC. 417
14.2.3 AMGEN INC. 418
14.2.4 MERCK KGAA 419
14.2.5 ALNYLAM PHARMACEUTICALS, INC. 420
14.2.6 INCYTE 421
14.2.7 ARUP LABORATORIES 422
14.2.8 DEVYSER 423
14.2.9 DIASORIN S.P.A. 424
14.2.10 TEMPUS 426
14.2.11 PILLAR BIOSCIENCES INC. 427
14.2.12 INVIVOSCRIBE, INC. 428
14.2.13 NEUROCODE 429
14.2.14 C₂N DIAGNOSTICS 430
14.2.15 TRINITY BIOTECH 431
14.2.16 AMOY DIAGNOSTICS CO., LTD. 432
15 APPENDIX 434
15.1 DISCUSSION GUIDE 434
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 441
15.3 CUSTOMIZATION OPTIONS 443
15.4 RELATED REPORTS 444
15.5 AUTHOR DETAILS 445
LIST OF TABLES
TABLE 1 PRECISION DIAGNOSTICS AND MEDICINE MARKET: INCLUSIONS AND EXCLUSIONS 36
TABLE 2 PRECISION DIAGNOSTICS AND MEDICINE MARKET: RISK ASSESSMENT 52
TABLE 3 PRECISION DIAGNOSTICS AND MEDICINE MARKET: IMPACT ANALYSIS
OF MARKET DYNAMICS 65
TABLE 4 AVERAGE SELLING PRICE TREND OF PRECISION DIAGNOSTIC TESTS,
BY KEY PLAYER, 2021–2023 (USD) 71
TABLE 5 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS,
BY KEY PLAYER, 2021–2023 (USD) 72
TABLE 6 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS,
BY REGION, 2021–2023 (USD) 73
TABLE 7 PRECISION DIAGNOSTICS AND MEDICINE MARKET: ROLE OF COMPANIES IN ECOSYSTEM 80
TABLE 8 PRECISION MEDICINE PRODUCTS IN CLINICAL PIPELINE, 2025–2029 81
TABLE 9 PRECISION DIAGNOSTIC TESTS APPROVED BY FDA 83
TABLE 10 PRECISION DIAGNOSTIC PRODUCTS ANALYSIS 95
TABLE 11 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 99
TABLE 12 PRECISION DIAGNOSTICS AND MEDICINE MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2019–2024 101
TABLE 13 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019–2023 (USD THOUSAND) 102
TABLE 14 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019–2023 (TONS) 103
TABLE 15 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019–2023 (USD THOUSAND) 104
TABLE 16 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS FOR HS CODE 382200, 2019–2023 (TONS) 105
TABLE 17 PRECISION DIAGNOSTICS AND MEDICINE MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 106
TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110
TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111
TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111
TABLE 22 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 112
TABLE 23 PRECISION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 112
TABLE 24 PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 114
TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION DIAGNOSTIC PRODUCTS, BY TYPE 116
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION MEDICINE PRODUCTS, BY PRODUCT 118
TABLE 27 BUYING CRITERIA FOR PRECISION DIAGNOSTIC PRODUCTS, BY END USER 119
TABLE 28 BUYING CRITERIA FOR PRECISION MEDICINE PRODUCTS, BY END USER 120
TABLE 29 PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 125
TABLE 30 PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION,
2022–2029 (USD BILLION) 126
TABLE 31 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022–2029 (USD BILLION) 126
TABLE 32 EUROPE: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 126
TABLE 33 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022–2029 (USD BILLION) 127
TABLE 34 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2022–2029 (USD BILLION) 127
TABLE 35 PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY REGION,
2022–2029 (USD BILLION) 128
TABLE 36 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING,
BY COUNTRY, 2022–2029 (USD BILLION) 128
TABLE 37 EUROPE: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 129
TABLE 38 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING, BY COUNTRY, 2022–2029 (USD BILLION) 129
TABLE 39 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR DTC TESTING,
BY COUNTRY, 2022–2029 (USD BILLION) 129
TABLE 40 PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY REGION,
2022–2029 (USD BILLION) 130
TABLE 41 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES,
BY COUNTRY, 2022–2029 (USD BILLION) 130
TABLE 42 EUROPE: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022–2029 (USD BILLION) 131
TABLE 43 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES, BY COUNTRY, 2022–2029 (USD BILLION) 131
TABLE 44 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER TYPES,
BY COUNTRY, 2022–2029 (USD BILLION) 131
TABLE 45 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 133
TABLE 46 PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION,
2022–2029 (USD BILLION) 134
TABLE 47 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY COUNTRY, 2022–2029 (USD BILLION) 134
TABLE 48 EUROPE: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2029 (USD BILLION) 135
TABLE 49 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 135
TABLE 50 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 135
TABLE 51 PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY REGION,
2022–2029 (USD BILLION) 136
TABLE 52 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY,
BY COUNTRY, 2022–2029 (USD BILLION) 137
TABLE 53 EUROPE: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 137
TABLE 54 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 137
TABLE 55 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR NEUROLOGY,
BY COUNTRY, 2022–2029 (USD BILLION) 138
TABLE 56 PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY REGION,
2022–2029 (USD BILLION) 139
TABLE 57 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2022–2029 (USD BILLION) 139
TABLE 58 EUROPE: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2022–2029 (USD BILLION) 139
TABLE 59 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 140
TABLE 60 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2022–2029 (USD BILLION) 140
TABLE 61 PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS,
BY REGION, 2022–2029 (USD BILLION) 141
TABLE 62 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 141
TABLE 63 EUROPE: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 141
TABLE 64 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 142
TABLE 65 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR OTHER DIAGNOSTIC INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 142
TABLE 66 PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 144
TABLE 67 PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2029 (USD BILLION) 145
TABLE 68 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD BILLION) 145
TABLE 69 EUROPE: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022–2029 (USD BILLION) 145
TABLE 70 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2022–2029 (USD BILLION) 146
TABLE 71 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD BILLION) 146
TABLE 72 PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION,
2022–2029 (USD BILLION) 147
TABLE 73 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS,
BY COUNTRY, 2022–2029 (USD BILLION) 147
TABLE 74 EUROPE: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY,
2022–2029 (USD BILLION) 147
TABLE 75 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION) 148
TABLE 76 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION) 148
TABLE 77 PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2029 (USD BILLION) 149
TABLE 78 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD BILLION) 149
TABLE 79 EUROPE: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD BILLION) 149
TABLE 80 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD BILLION) 150
TABLE 81 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD BILLION) 150
TABLE 82 PRECISION MEDICINE MARKET, BY TYPE, 2022–2029 (USD BILLION) 152
TABLE 83 PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022–2029 (USD BILLION) 153
TABLE 84 NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2029 (USD BILLION) 153
TABLE 85 EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2022–2029 (USD BILLION) 153
TABLE 86 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2022–2029 (USD BILLION) 154
TABLE 87 LATIN AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2029 (USD BILLION) 154
TABLE 88 PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION,
2022–2029 (USD BILLION) 155
TABLE 89 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS,
BY COUNTRY, 2022–2029 (USD BILLION) 155
TABLE 90 EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 156
TABLE 91 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS,
BY COUNTRY, 2022–2029 (USD BILLION) 156
TABLE 92 LATIN AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS,
BY COUNTRY, 2022–2029 (USD BILLION) 156
TABLE 93 PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY REGION,
2022–2029 (USD BILLION) 158
TABLE 94 NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022–2029 (USD BILLION) 158
TABLE 95 EUROPE: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES,
BY COUNTRY, 2022–2029 (USD BILLION) 158
TABLE 96 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES,
BY COUNTRY, 2022–2029 (USD BILLION) 159
TABLE 97 LATIN AMERICA: PRECISION MEDICINE MARKET FOR CELL & GENE THERAPIES,
BY COUNTRY, 2022–2029 (USD BILLION) 159
TABLE 98 PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS,
BY REGION, 2022–2029 (USD BILLION) 160
TABLE 99 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 160
TABLE 100 EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 160
TABLE 101 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 161
TABLE 102 LATIN AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTI-RETROVIRAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION) 161
TABLE 103 PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY REGION,
2022–2029 (USD BILLION) 162
TABLE 104 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2022–2029 (USD BILLION) 162
TABLE 105 EUROPE: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD BILLION) 162
TABLE 106 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2022–2029 (USD BILLION) 163
TABLE 107 LATIN AMERICA: PRECISION MEDICINE MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2022–2029 (USD BILLION) 163
TABLE 108 PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 165
TABLE 109 PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION,
2022–2029 (USD BILLION) 166
TABLE 110 NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 166
TABLE 111 EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2029 (USD BILLION) 166
TABLE 112 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 167
TABLE 113 LATIN AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD BILLION) 167
TABLE 114 PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION,
2022–2029 (USD BILLION) 168
TABLE 115 NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES,
BY COUNTRY, 2022–2029 (USD BILLION) 168
TABLE 116 EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 169
TABLE 117 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD BILLION) 169
TABLE 118 LATIN AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES,
BY COUNTRY, 2022–2029 (USD BILLION) 169
TABLE 119 PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION,
2022–2029 (USD BILLION) 170
TABLE 120 NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD BILLION) 170
TABLE 121 EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD BILLION) 171
TABLE 122 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD BILLION) 171
TABLE 123 LATIN AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2022–2029 (USD BILLION) 171
TABLE 124 PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2022–2029 (USD BILLION) 172
TABLE 125 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD BILLION) 173
TABLE 126 EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS,
BY COUNTRY, 2022–2029 (USD BILLION) 173
TABLE 127 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD BILLION) 173
TABLE 128 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD BILLION) 174
TABLE 129 PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY REGION, 2022–2029 (USD BILLION) 175
TABLE 130 NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 175
TABLE 131 EUROPE: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS,
BY COUNTRY, 2022–2029 (USD BILLION) 175
TABLE 132 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 176
TABLE 133 LATIN AMERICA: PRECISION MEDICINE MARKET FOR OTHER MEDICINE INDICATIONS, BY COUNTRY, 2022–2029 (USD BILLION) 176
TABLE 134 PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD MILLION) 178
TABLE 135 PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY REGION,
2022–2029 (USD MILLION) 179
TABLE 136 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 137 EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 138 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 139 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 140 PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION,
2022–2029 (USD MILLION) 181
TABLE 141 NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 142 EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 143 ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 144 LATIN AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 145 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION,
2022–2029 (USD BILLION) 184
TABLE 146 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE,
2022–2029 (USD BILLION) 185
TABLE 147 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 186
TABLE 148 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 186
TABLE 149 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 186
TABLE 150 NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 187
TABLE 151 NORTH AMERICA: PRECISION MEDICINE MARKET, END USER,
2022–2029 (USD BILLION) 187
TABLE 152 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY COUNTRY,
2022–2029 (USD BILLION) 187
TABLE 153 NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY,
2022–2029 (USD BILLION) 188
TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 188
TABLE 155 US: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 189
TABLE 156 US: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 190
TABLE 157 US: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 190
TABLE 158 US: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 190
TABLE 159 US: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 191
TABLE 160 US: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 191
TABLE 161 CANADA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 192
TABLE 162 CANADA: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 192
TABLE 163 CANADA: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 192
TABLE 164 CANADA: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 193
TABLE 165 CANADA: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 193
TABLE 166 CANADA: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 193
TABLE 167 EUROPE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 194
TABLE 168 EUROPE: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 194
TABLE 169 EUROPE: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 195
TABLE 170 EUROPE: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 195
TABLE 171 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 195
TABLE 172 EUROPE: PRECISION MEDICINE MARKET, BY END USER,
2022–2029 (USD BILLION) 196
TABLE 173 EUROPE: PRECISION DIAGNOSTICS MARKET, BY COUNTRY,
2022–2029 (USD BILLION) 196
TABLE 174 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY,
2022–2029 (USD BILLION) 196
TABLE 175 EUROPE: KEY MACROECONOMIC INDICATORS 198
TABLE 176 GERMANY: PRECISION DIAGNOSTICS MARKET, BY TYPE,
2022–2029 (USD BILLION) 199
TABLE 177 GERMANY: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 199
TABLE 178 GERMANY: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 200
TABLE 179 GERMANY: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 200
TABLE 180 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 200
TABLE 181 GERMANY: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 201
TABLE 182 UK: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 202
TABLE 183 UK: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 202
TABLE 184 UK: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 202
TABLE 185 UK: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 203
TABLE 186 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 203
TABLE 187 UK: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 203
TABLE 188 FRANCE: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 204
TABLE 189 FRANCE: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 204
TABLE 190 FRANCE: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 205
TABLE 191 FRANCE: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 205
TABLE 192 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 205
TABLE 193 FRANCE: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 206
TABLE 194 ITALY: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 206
TABLE 195 ITALY: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 207
TABLE 196 ITALY: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 207
TABLE 197 ITALY: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 207
TABLE 198 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 208
TABLE 199 ITALY: PRECISION MEDICINE MARKET, END USER, 2022–2029 (USD BILLION) 208
TABLE 200 SPAIN: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 209
TABLE 201 SPAIN: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 209
TABLE 202 SPAIN: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 209
TABLE 203 SPAIN: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 210
TABLE 204 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 210
TABLE 205 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 210
TABLE 206 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY TYPE,
2022–2029 (USD BILLION) 211
TABLE 207 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 211
TABLE 208 REST OF EUROPE: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 212
TABLE 209 REST OF EUROPE: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 212
TABLE 210 REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 212
TABLE 211 REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER,
2022–2029 (USD BILLION) 213
TABLE 212 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY TYPE,
2022–2029 (USD BILLION) 213
TABLE 213 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 214
TABLE 214 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 214
TABLE 215 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 214
TABLE 216 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 215
TABLE 217 ASIA PACIFIC: PRECISION MEDICINE MARKET, END USER,
2022–2029 (USD BILLION) 215
TABLE 218 ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY COUNTRY,
2022–2029 (USD BILLION) 215
TABLE 219 ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY,
2022–2029 (USD BILLION) 216
TABLE 220 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 216
TABLE 221 CHINA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 217
TABLE 222 CHINA: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 217
TABLE 223 CHINA: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 218
TABLE 224 CHINA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 218
TABLE 225 CHINA: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 218
TABLE 226 CHINA: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 219
TABLE 227 JAPAN: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 220
TABLE 228 JAPAN: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 220
TABLE 229 JAPAN: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 220
TABLE 230 JAPAN: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 221
TABLE 231 JAPAN: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 221
TABLE 232 JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 221
TABLE 233 INDIA: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 222
TABLE 234 INDIA: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 222
TABLE 235 INDIA: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 223
TABLE 236 INDIA: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 223
TABLE 237 INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2022–2029 (USD BILLION) 223
TABLE 238 INDIA: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 224
TABLE 239 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY TYPE,
2022–2029 (USD BILLION) 224
TABLE 240 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 225
TABLE 241 AUSTRALIA: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 225
TABLE 242 AUSTRALIA: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 225
TABLE 243 AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 226
TABLE 244 AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER,
2022–2029 (USD BILLION) 226
TABLE 245 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY TYPE,
2022–2029 (USD BILLION) 226
TABLE 246 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 227
TABLE 247 REST OF ASIA PACIFIC: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 227
TABLE 248 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 227
TABLE 249 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 228
TABLE 250 REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER,
2022–2029 (USD BILLION) 228
TABLE 251 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE,
2022–2029 (USD BILLION) 229
TABLE 252 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 229
TABLE 253 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 229
TABLE 254 LATIN AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 230
TABLE 255 LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 230
TABLE 256 LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER,
2022–2029 (USD BILLION) 230
TABLE 257 LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY COUNTRY,
2022–2029 (USD BILLION) 231
TABLE 258 LATIN AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY,
2022–2029 (USD BILLION) 231
TABLE 259 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 232
TABLE 260 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 233
TABLE 261 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 233
TABLE 262 BRAZIL: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 233
TABLE 263 BRAZIL: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 234
TABLE 264 BRAZIL: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 234
TABLE 265 BRAZIL: PRECISION MEDICINE MARKET, BY END USER, 2022–2029 (USD BILLION) 234
TABLE 266 MEXICO: PRECISION DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD BILLION) 235
TABLE 267 MEXICO: PRECISION DIAGNOSTICS MARKET, BY INDICATION,
2022–2029 (USD BILLION) 235
TABLE 268 MEXICO: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 236
TABLE 269 MEXICO: PRECISION MEDICINE MARKET, BY PRODUCT, 2022–2029 (USD BILLION) 236
TABLE 270 MEXICO: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 236
TABLE 271 MEXICO: PRECISION MEDICINE MARKET, BY END USER,
2022–2029 (USD BILLION) 237
TABLE 272 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE,
2022–2029 (USD BILLION) 237
TABLE 273 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 238
TABLE 274 REST OF LATIN AMERICA: PRECISION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD BILLION) 238
TABLE 275 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 238
TABLE 276 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 239
TABLE 277 REST OF LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER,
2022–2029 (USD BILLION) 239
TABLE 278 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY TYPE,
2022–2029 (USD BILLION) 240
TABLE 279 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD BILLION) 240
TABLE 280 MIDDLE EAST & AFRICA: PRECISION DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD BILLION) 241
TABLE 281 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY PRODUCT,
2022–2029 (USD BILLION) 241
TABLE 282 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY INDICATION,
2022–2029 (USD BILLION) 241
TABLE 283 MIDDLE EAST & AFRICA: PRECISION MEDICINE MARKET, BY END USER,
2022–2029 (USD BILLION) 242
TABLE 284 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 243
TABLE 285 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PRECISION DIAGNOSTICS MARKET, JANUARY 2021–NOVEMBER 2024 245
TABLE 286 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PRECISION MEDICINE MARKET, JANUARY 2021–NOVEMBER 2024 248
TABLE 287 PRECISION DIAGNOSTICS MARKET: DEGREE OF COMPETITION 255
TABLE 288 PRECISION MEDICINE MARKET: DEGREE OF COMPETITION 258
TABLE 289 PRECISION DIAGNOSTICS MARKET: REGION FOOTPRINT 263
TABLE 290 PRECISION DIAGNOSTICS MARKET: TYPE FOOTPRINT 264
TABLE 291 PRECISION DIAGNOSTICS MARKET: INDICATION FOOTPRINT 265
TABLE 292 PRECISION MEDICINE MARKET: REGION FOOTPRINT 270
TABLE 293 PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT 271
TABLE 294 PRECISION MEDICINE MARKET: INDICATION FOOTPRINT 272
TABLE 295 PRECISION DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 276
TABLE 296 PRECISION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 277
TABLE 297 PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES 280
TABLE 298 PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 281
TABLE 299 PRECISION DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 286
TABLE 300 PRECISION DIAGNOSTICS MARKET: DEALS, JANUARY 2021–NOVEMBER 2024 287
TABLE 301 PRECISION DIAGNOSTICS MARKET: EXPANSIONS,
JANUARY 2021–NOVEMBER 2024 288
TABLE 302 PRECISION MEDICINE MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 289
TABLE 303 PRECISION MEDICINE MARKET: DEALS, JANUARY 2021–NOVEMBER 2024 290
TABLE 304 PRECISION MEDICINE: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 291
TABLE 305 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): COMPANY OVERVIEW 292
TABLE 306 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): PRODUCTS OFFERED 293
TABLE 307 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 297
TABLE 308 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): DEALS,
JANUARY 2021–NOVEMBER 2024 298
TABLE 309 ABBOTT: COMPANY OVERVIEW 300
TABLE 310 ABBOTT: PRODUCTS OFFERED 301
TABLE 311 ABBOTT: DEALS, JANUARY 2021–NOVEMBER 2024 302
TABLE 312 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 304
TABLE 313 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 305
TABLE 314 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 307
TABLE 315 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 308
TABLE 316 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 308
TABLE 317 GUARDANT HEALTH: COMPANY OVERVIEW 310
TABLE 318 GUARDANT HEALTH: PRODUCTS OFFERED 311
TABLE 319 GUARDANT HEALTH: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–NOVEMBER 2024 312
TABLE 320 GUARDANT HEALTH: DEALS, JANUARY 2021–NOVEMBER 2024 314
TABLE 321 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW 316
TABLE 322 EXACT SCIENCES CORPORATION: PRODUCTS OFFERED 317
TABLE 323 EXACT SCIENCES CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 318
TABLE 324 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024 319
TABLE 325 QIAGEN: COMPANY OVERVIEW 320
TABLE 326 QIAGEN: PRODUCTS OFFERED 321
TABLE 327 QIAGEN: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–NOVEMBER 2024 324
TABLE 328 QIAGEN: DEALS, JANUARY 2021–NOVEMBER 2024 325
TABLE 329 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 326
TABLE 330 MYRIAD GENETICS, INC.: PRODUCTS OFFERED 327
TABLE 331 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–NOVEMBER 2024 329
TABLE 332 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 329
TABLE 333 MYRIAD GENETICS, INC.: OTHER DEVELOPMENTS,
JANUARY 2021–NOVEMBER 2024 330
TABLE 334 NATERA, INC.: COMPANY OVERVIEW 331
TABLE 335 NATERA, INC.: PRODUCTS OFFERED 332
TABLE 336 NATERA, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–NOVEMBER 2024 334
TABLE 337 NATERA, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 334
TABLE 338 ILLUMINA, INC.: COMPANY OVERVIEW 335
TABLE 339 ILLUMINA, INC.: PRODUCTS OFFERED 336
TABLE 340 ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 337
TABLE 341 ILLUMINA, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 337
TABLE 342 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 339
TABLE 343 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 340
TABLE 344 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 341
TABLE 345 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–NOVEMBER 2024 342
TABLE 346 DANAHER: COMPANY OVERVIEW 344
TABLE 347 DANAHER: PRODUCTS OFFERED 345
TABLE 348 DANAHER: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–NOVEMBER 2024 348
TABLE 349 DANAHER: DEALS, JANUARY 2021–NOVEMBER 2024 349
TABLE 350 23ANDME, INC.: COMPANY OVERVIEW 350
TABLE 351 23ANDME, INC.: PRODUCTS OFFERED 351
TABLE 352 23ANDME, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 353
TABLE 353 MERCK & CO., INC.: COMPANY OVERVIEW 354
TABLE 354 MERCK & CO., INC.: PRODUCTS OFFERED 355
TABLE 355 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024 356
TABLE 356 MERCK & CO., INC.: DEALS, JANUARY 2021–NOVEMBER 2024 360
TABLE 357 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 361
TABLE 358 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 362
TABLE 359 GILEAD SCIENCES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 364
TABLE 360 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 365
TABLE 361 F. HOFFMANN-LA ROCHE LTD (MEDICINE): COMPANY OVERVIEW 367
TABLE 362 F. HOFFMANN-LA ROCHE LTD (MEDICINE): PRODUCTS OFFERED 368
TABLE 363 F. HOFFMANN-LA ROCHE LTD (MEDICINE): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 371
TABLE 364 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 373
TABLE 365 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED 374
TABLE 366 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 376
TABLE 367 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021–NOVEMBER 2024 378
TABLE 368 NOVARTIS AG: COMPANY OVERVIEW 379
TABLE 369 NOVARTIS AG: PRODUCTS OFFERED 380
TABLE 370 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–NOVEMBER 2024 383
TABLE 371 NOVARTIS AG: DEALS, JANUARY 2021–NOVEMBER 2024 384
TABLE 372 ASTRAZENECA: COMPANY OVERVIEW 386
TABLE 373 ASTRAZENECA: PRODUCTS OFFERED 387
TABLE 374 ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 389
TABLE 375 ASTRAZENECA: DEALS, JANUARY 2021–NOVEMBER 2024 390
TABLE 376 ABBVIE INC.: COMPANY OVERVIEW 391
TABLE 377 ABBVIE INC.: PRODUCTS OFFERED 392
TABLE 378 ABBVIE INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–NOVEMBER 2024 393
TABLE 379 ABBVIE INC.: DEALS, JANUARY 2021–NOVEMBER 2024 393
TABLE 380 ABBVIE INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 394
TABLE 381 LILLY: COMPANY OVERVIEW 395
TABLE 382 LILLY: PRODUCTS OFFERED 396
TABLE 383 LILLY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 397
TABLE 384 LILLY: DEALS, JANUARY 2021–NOVEMBER 2024 398
TABLE 385 PFIZER INC.: COMPANY OVERVIEW 399
TABLE 386 PFIZER INC.: PRODUCTS OFFERED 400
TABLE 387 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–NOVEMBER 2024 402
TABLE 388 PFIZER INC.: DEALS, JANUARY 2021–NOVEMBER 2024 402
TABLE 389 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 403
TABLE 390 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED 404
TABLE 391 SAREPTA THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 405
TABLE 392 SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 406
TABLE 393 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY OVERVIEW 407
TABLE 394 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCTS OFFERED 408
TABLE 395 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–NOVEMBER 2024 409
TABLE 396 VERTEX PHARMACEUTICALS INCORPORATED: DEALS,
JANUARY 2021–NOVEMBER 2024 410
TABLE 397 GSK PLC.: COMPANY OVERVIEW 411
TABLE 398 GSK PLC.: PRODUCTS OFFERED 412
TABLE 399 GSK PLC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–NOVEMBER 2024 413
TABLE 400 GSK PLC.: DEALS, JANUARY 2021–NOVEMBER 2024 414
TABLE 401 SANOFI: COMPANY OVERVIEW 416
TABLE 402 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 417
TABLE 403 AMGEN INC.: COMPANY OVERVIEW 418
TABLE 404 MERCK KGAA: COMPANY OVERVIEW 419
TABLE 405 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 420
TABLE 406 INCYTE: COMPANY OVERVIEW 421
TABLE 407 ARUP LABORATORIES: COMPANY OVERVIEW 422
TABLE 408 DEVYSER: COMPANY OVERVIEW 423
TABLE 409 DIASORIN S.P.A.: COMPANY OVERVIEW 424
TABLE 410 TEMPUS: COMPANY OVERVIEW 426
TABLE 411 PILLAR BIOSCIENCES INC.: COMPANY OVERVIEW 427
TABLE 412 INVIVOSCRIBE, INC.: COMPANY OVERVIEW 428
TABLE 413 NEUROCODE: COMPANY OVERVIEW 429
TABLE 414 C₂N DIAGNOSTICS: COMPANY OVERVIEW 430
TABLE 415 TRINITY BIOTECH: COMPANY OVERVIEW 431
TABLE 416 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 432
LIST OF FIGURES
FIGURE 1 PRECISION DIAGNOSTICS AND MEDICINE MARKET SEGMENTATION 35
FIGURE 2 PRECISION DIAGNOSTICS AND MEDICINE MARKET: RESEARCH DESIGN 39
FIGURE 3 PRECISION DIAGNOSTICS AND MEDICINE MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 41
FIGURE 4 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 42
FIGURE 5 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 42
FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD:
REVENUE SHARE ANALYSIS, 2023 43
FIGURE 7 PRECISION MEDICINE MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 44
FIGURE 8 PRECISION MEDICINE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 45
FIGURE 9 ILLUSTRATIVE EXAMPLE OF MERCK & CO., INC.: REVENUE SHARE ANALYSIS, 2023 45
FIGURE 10 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 46
FIGURE 11 PRECISION DIAGNOSTICS MARKET SIZE ESTIMATION METHODOLOGY:
TOP-DOWN APPROACH 47
FIGURE 12 PRECISION MEDICINE MARKET SIZE ESTIMATION METHODOLOGY:
TOP-DOWN APPROACH 48
FIGURE 13 PRECISION DIAGNOSTICS MARKET: CAGR PROJECTIONS, 2024–2029 49
FIGURE 14 PRECISION MEDICINE MARKET: CAGR PROJECTIONS, 2024–2029 50
FIGURE 15 PRECISION DIAGNOSTICS AND MEDICINE MARKET:
GROWTH ANALYSIS OF MARKET DYNAMICS 50
FIGURE 16 PRECISION DIAGNOSTICS AND MEDICINE MARKET: DATA TRIANGULATION 51
FIGURE 17 PRECISION DIAGNOSTICS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION) 53
FIGURE 18 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD BILLION) 54
FIGURE 19 PRECISION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD BILLION) 54
FIGURE 20 PRECISION MEDICINE MARKET, BY PRODUCT, 2024 VS. 2029 (USD BILLION) 55
FIGURE 21 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029 (USD BILLION) 55
FIGURE 22 PRECISION MEDICINE MARKET, BY END USER, 2024 VS. 2029 (USD BILLION) 56
FIGURE 23 GEOGRAPHICAL SNAPSHOT OF PRECISION DIAGNOSTICS MARKET, 2024–2029 56
FIGURE 24 GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET, 2024–2029 57
FIGURE 25 INCREASING DEMAND FOR QUICK AND ACCURATE DIAGNOSTIC TESTS TO DRIVE PRECISION DIAGNOSTICS MARKET 58
FIGURE 26 INCREASING NUMBER OF REGULATORY APPROVALS FOR PERSONALIZED MEDICINES TO DRIVE PRECISION MEDICINE MARKET 59
FIGURE 27 GENETIC TESTING SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF PRECISION DIAGNOSTICS MARKET IN 2023 60
FIGURE 28 ONCOLOGY SEGMENT TO HAVE LARGEST MARKET
SHARE DURING FORECAST PERIOD 60
FIGURE 29 HOME CARE SETTINGS MARKET COMMANDED HIGHEST SHARE IN 2023 61
FIGURE 30 MONOCLONAL ANTIBODIES AND US LED NORTH AMERICAN PRECISION MEDICINE MARKET IN 2023 61
FIGURE 31 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 62
FIGURE 32 JAPAN TO REGISTER HIGHEST GROWTH IN PRECISION DIAGNOSTICS MARKET DURING FORECAST PERIOD 62
FIGURE 33 GERMANY TO REGISTER HIGHEST GROWTH IN PRECISION MEDICINE MARKET DURING FORECAST PERIOD 63
FIGURE 34 PRECISION DIAGNOSTICS AND MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
FIGURE 35 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN PRECISION DIAGNOSTICS AND MEDICINE MARKET 70
FIGURE 36 AVERAGE SELLING PRICE TREND OF PRECISION DIAGNOSTIC TESTS, BY KEY PLAYER, 2021–2023 (USD) 71
FIGURE 37 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS,
BY KEY PLAYER, 2021–2023 (USD) 73
FIGURE 38 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS,
BY REGION, 2021–2023 (USD) 74
FIGURE 39 PRECISION DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 75
FIGURE 40 PRECISION MEDICINE MARKET: VALUE CHAIN ANALYSIS 76
FIGURE 41 PRECISION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 78
FIGURE 42 PRECISION MEDICINE MARKET: SUPPLY CHAIN ANALYSIS 79
FIGURE 43 PRECISION DIAGNOSTICS AND MEDICINE MARKET: ECOSYSTEM ANALYSIS 80
FIGURE 44 PRECISION DIAGNOSTICS AND MEDICINE MARKET: PATENT ANALYSIS, JANUARY 2014–NOVEMBER 2024 100
FIGURE 45 PRECISION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 113
FIGURE 46 PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 115
FIGURE 47 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION DIAGNOSTIC PRODUCTS, BY TYPE 117
FIGURE 48 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRECISION MEDICINE PRODUCTS, BY PRODUCT 118
FIGURE 49 KEY BUYING CRITERIA FOR PRECISION DIAGNOSTIC PRODUCTS, BY END USER 119
FIGURE 50 KEY BUYING CRITERIA FOR PRECISION MEDICINE PRODUCTS, BY END USER 120
FIGURE 51 NORTH AMERICA: PRECISION DIAGNOSTICS AND MEDICINE MARKET SNAPSHOT 185
FIGURE 52 EUROPE: PRECISION DIAGNOSTICS AND MEDICINE MARKET SNAPSHOT 197
FIGURE 53 PRECISION DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD MILLION) 252
FIGURE 54 PRECISION MEDICINE MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD MILLION) 253
FIGURE 55 PRECISION DIAGNOSTICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 254
FIGURE 56 PRECISION DIAGNOSTICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 257
FIGURE 57 PRECISION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 261
FIGURE 58 PRECISION DIAGNOSTICS MARKET: COMPANY FOOTPRINT 262
FIGURE 59 PRECISION MEDICINE MARKET: COMPANY EVALUATION
MATRIX (KEY PLAYERS), 2023 268
FIGURE 60 PRECISION MEDICINE MARKET: COMPANY FOOTPRINT 269
FIGURE 61 PRECISION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 275
FIGURE 62 PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 279
FIGURE 63 PRECISION DIAGNOSTICS MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 282
FIGURE 64 PRECISION DIAGNOSTICS MARKET: EV/EBITDA OF KEY VENDORS, 2024 282
FIGURE 65 PRECISION MEDICINE MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 283
FIGURE 66 PRECISION MEDICINE MARKET: EV/EBITDA OF KEY VENDORS, 2024 283
FIGURE 67 PRECISION DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON 284
FIGURE 68 PRECISION MEDICINE MARKET: BRAND/PRODUCT COMPARISON 285
FIGURE 69 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS): COMPANY SNAPSHOT (2023) 293
FIGURE 70 ABBOTT: COMPANY SNAPSHOT (2023) 301
FIGURE 71 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 305
FIGURE 72 GUARDANT HEALTH: COMPANY SNAPSHOT (2023) 311
FIGURE 73 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2023) 317
FIGURE 74 QIAGEN: COMPANY SNAPSHOT (2023) 321
FIGURE 75 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023) 327
FIGURE 76 NATERA, INC.: COMPANY SNAPSHOT (2023) 332
FIGURE 77 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 336
FIGURE 78 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 340
FIGURE 79 DANAHER: COMPANY SNAPSHOT (2023) 345
FIGURE 80 23ANDME, INC.: COMPANY SNAPSHOT (2023) 351
FIGURE 81 MERCK & CO., INC.: COMPANY SNAPSHOT (2023) 355
FIGURE 82 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023) 362
FIGURE 83 F. HOFFMANN-LA ROCHE LTD (MEDICINE): COMPANY SNAPSHOT (2023) 368
FIGURE 84 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023) 374
FIGURE 85 NOVARTIS AG: COMPANY SNAPSHOT (2023) 380
FIGURE 86 ASTRAZENECA: COMPANY SNAPSHOT (2023) 387
FIGURE 87 ABBVIE INC.: COMPANY SNAPSHOT (2023) 392
FIGURE 88 LILLY: COMPANY SNAPSHOT (2023) 396
FIGURE 89 PFIZER INC.: COMPANY SNAPSHOT (2023) 400
FIGURE 90 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2023) 404
FIGURE 91 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT (2023) 408
FIGURE 92 GSK PLC.: COMPANY SNAPSHOT (2023) 412
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11